Literature DB >> 8327702

Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.

E F Patz1, V J Lowe, J M Hoffman, S S Paine, P Burrowes, R E Coleman, P C Goodman.   

Abstract

The authors assessed the role of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) in differentiation of benign from malignant focal pulmonary abnormalities seen on chest radiographs. Fifty-one patients underwent FDG PET scanning. Focal abnormalities at radiography included solitary pulmonary nodules (n = 38), pulmonary masses (n = 5), and poorly marginated infiltrates or opacities (n = 8). Proof of diagnosis was obtained by means of transbronchial biopsy (n = 21), open lung biopsy (n = 14), percutaneous needle biopsy (n = 14), or cytologic evaluation of sputum (n = 1). A nodule in one patient had been radiographically stable for at least 8 years. Quantitative analysis was performed by calculation of a standardized uptake ratio (SUR). Thirty-three malignant lesions had a mean SUR (+/- 1 standard deviation) of 6.5 +/- 2.9. Eighteen benign lesions had a mean SUR of 1.7 +/- 1.2. For a benign lesion with SUR of 2.5 or less, specificity of FDG PET was 100%, while sensitivity was 89%. These results suggest that FDG PET is accurate in differentiation of benign from malignant focal pulmonary abnormalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327702     DOI: 10.1148/radiology.188.2.8327702

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  62 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

2.  Guidelines for radiologically guided lung biopsy.

Authors:  A Manhire; M Charig; C Clelland; F Gleeson; R Miller; H Moss; K Pointon; C Richardson; E Sawicka
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

3.  [Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules].

Authors:  K Orino; M Kawamura; J Hatazawa; I Suzuki; Y Sazawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

4.  Diaphragmatic hernia masquerading as a pulmonary metastasis.

Authors:  J V Lodhia; S Appiah; P Tcherveniakov; P Krysiak
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

5.  Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues.

Authors:  Yingbing Wang; Edison Chiu; Jarrett Rosenberg; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

Review 6.  Management of an incidentally discovered pulmonary nodule.

Authors:  Catherine Beigelman-Aubry; Catherine Hill; Philippe A Grenier
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

7.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

8.  Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT.

Authors:  Suzanne L Aquino; Landon B Kuester; Victorine V Muse; Elkan F Halpern; Alan J Fischman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-03       Impact factor: 9.236

Review 9.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 10.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.